# Developmental Funds

> **NIH NIH P30** · H. LEE MOFFITT CANCER CTR & RES INST · 2022 · $162,193

## Abstract

PROJECT SUMMARY
DEVELOPMENTAL FUNDS
As Center Director, Dr. Cleveland provides leadership and oversight of all of the research activities of Moffitt
Cancer Center (Moffitt), including setting the strategic vision and Research Strategic Plan (RSP); faculty
recruitment, development, retention and support (including focus on promotion and tenure and underrepresented
faculty); clinical trials and physician research protected time; and allocation of all resources and activities,
including staff, equipment and space. Dr. Cleveland deploys Developmental Funds to achieve the RSP and to
foster transdisciplinary science across Moffitt. Specifically, this includes Developmental Pilot Projects; Staff
Investigators for four Centers of Excellence whose mission is to support the research of all five CCSG Programs;
and an Early Stage Clinical Investigator. Developmental Funds are leveraged with institutional funds.
Developmental Funds: CCSG Developmental Funds are critical for realizing the RSP. These funds will be
deployed for Team Science projects ($100,000 per year) that foster high impact transdisciplinary, translational
science. These funds are leveraged with significant institutional funds that support these pilot projects, which
ultimately were the only category for which CCSG Developmental Funds were used. Notably this investment of
CCSG and institutional funds returned more than $27.4 million in peer-reviewed funding and 29 publications.
Staff Investigators: Moffitt’s Centers of Excellence build and foster transdisciplinary collaborations across all
Research Programs based on areas of institutional strength that align with the needs of the catchment area.
Each Center of Excellence is led by a scientifically accomplished Staff Investigator, who reports directly to the
Associate Center Director (ACD) of Translational Science: 1) Alexander R. A. Anderson, PhD (Evolutionary
Therapy); 2) Anna R. Giuliano, PhD (Immunization & Infection Research); 3) Eric B. Haura, MD (Lung Cancer);
and 4) Kieran S. M. Smalley, PhD (Melanoma & Skin Cancer). Their efforts to drive collaboration in catchment
area priorities have produced extensive research over the award period. Effort of 1.20 calendar months (10%)
is requested for each Staff Investigator (totaling $96,203).
Early Stage Clinical Investigators: Moffitt will use CCSG funds (1.2 calendar months or 10% effort, $24,051)
to support at least one Early Stage Clinical Investigator (ESCI) each year by providing dedicated effort to develop
investigator-initiated trials (IITs) and to enroll patients on these IITs. We will prioritize investigators from
underrepresented minority groups at the Assistant Member level. Each ESCI will work with Dr. Eric Haura,
Associate Center Director of Clinical Science, and their academic department chair to identify a mentoring
committee consisting of a primary mentor and 1 – 2 secondary mentors with at least one of the mentors being a
basic, population, or quantitative science expert in the ...

## Key facts

- **NIH application ID:** 10333168
- **Project number:** 2P30CA076292-24
- **Recipient organization:** H. LEE MOFFITT CANCER CTR & RES INST
- **Principal Investigator:** John L. Cleveland
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $162,193
- **Award type:** 2
- **Project period:** 1998-02-18 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10333168

## Citation

> US National Institutes of Health, RePORTER application 10333168, Developmental Funds (2P30CA076292-24). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10333168. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*